



# THE PATH OF LEAST RESISTANCE

**Standing Medical Advisory Committee**  
***Sub-Group on Antimicrobial Resistance***

# TABLE OF CONTENTS

<b>1</b>	<b>INTRODUCTION</b> 7
<b>2</b>	<b>RECOMMENDATIONS</b> 9
<b>3</b>	<b>LOOKING INTO THE ABYSS</b> 14
<b>4</b>	<b>ANTIMICROBIAL AGENTS</b> 17
<b>5</b>	<b>BASIS OF RESISTANCE</b> 20 <ul style="list-style-type: none"><li>5.1 Mutation 20</li><li>5.2 Gene transfer 21</li><li>5.3 Inherently resistant species 22</li><li>5.4 Multi-resistance 22</li></ul>
<b>6</b>	<b>DOES USE OF ANTIMICROBIAL AGENTS CAUSE RESISTANCE?</b> 24
<b>7</b>	<b>TO PRESCRIBE OR NOT TO PRESCRIBE?</b> 25
<b>8</b>	<b>WHERE ARE ANTIMICROBIAL AGENTS USED?</b> 29 <ul style="list-style-type: none"><li>8.1 Community prescribing 29</li><li>8.2 Prescribing in hospitals 30</li></ul>
<b>9</b>	<b>THE EXTENT OF BACTERIAL RESISTANCE IN THE UK</b> 32
<b>10</b>	<b>CURRENT RESISTANCE PROBLEMS IN THE UK AND WORLD-WIDE</b> 33 <ul style="list-style-type: none"><li>10.1 Methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) 33</li><li>10.2 Enterococci 35</li><li>10.3 <i>Streptococcus pneumoniae</i> 36</li><li>10.4 Hospital-acquired gram-negative rods 38</li><li>10.5 Enteric pathogens 40</li><li>10.6 <i>Neisseria gonorrhoeae</i> 43</li><li>10.7 <i>Neisseria meningitidis</i> 45</li><li>10.8 <i>Mycobacterium tuberculosis</i> 46</li><li>10.9 Antifungal resistance 47</li><li>10.10 Fungal infections 49</li><li>10.11 Viral infections 53</li></ul>
<b>11</b>	<b>AREAS OF CLINICAL PRACTICE WHERE ANTIMICROBIAL RESISTANCE HAS, OR IS LIKELY TO HAVE, THE GREATEST IMPACT</b> 55 <ul style="list-style-type: none"><li>11.1 Intensive care units 55</li><li>11.2 Admissions wards 56</li><li>11.3 Other in-patients 57</li><li>11.4 Immunocompromised patients, including those with HIV infection 57</li><li>11.5 Out-patients 57</li><li>11.6 Dental use of antimicrobial agents 58</li></ul>
<b>12</b>	<b>WHAT PRACTICES BY CLINICIANS AND THE PUBLIC PREDISPOSE TO THE DEVELOPMENT OF ANTIMICROBIAL RESISTANCE?</b> 60 <ul style="list-style-type: none"><li>12.1 Total antimicrobial usage 60</li></ul>

- 12.2 Factors relating to particular antimicrobial agents 61
- 12.3 Disturbance of the normal bacterial flora and resistant super-infection 62
- 12.4 Selection of resistant commensal bacteria 62
- 12.5 Regimen 63
- 12.6 Route 64
- 12.7 Current variations in dosage and duration of therapy 66
- 12.8 Selection factors related to the type of clinical usage 66
- 12.9 Cross-infection and the spread of resistance 71
- 12.10 Public behaviour and social change 72
- 12.11 Short-term gain and long-term cost 75
- 12.12 Veterinary use of antimicrobial agents and the emergence of resistance 76

**13**

### **PREVENTING THE DEVELOPMENT OF ANTIMICROBIAL RESISTANCE 81**

- 13.1 Do good prescribing practices prevent or slow the development of resistance? 81
- 13.2 Should resistance decline if use of antimicrobial agents is restricted? 81
- 13.3 Does resistance disappear if the use of antimicrobial agents is restricted? 82

**14**

### **DEVELOPMENT OF NEW ANTIMICROBIAL AGENTS 87**

**15**

### **PROMOTING GOOD PRACTICE 91**

**16**

### **PROMOTING BETTER PRESCRIBING 92**

- 16.1 Better prescribing 92
- 16.2 Promoting conservation of antimicrobial agents 98
- 16.3 Public expectations and attitudes to antimicrobial agents 100
- 16.4 Cherishing your flora – the beneficial nature of bacteria 102

**17**

### **SURVEILLANCE OF RESISTANCE 103**

- 17.1 Alert organism surveillance (exception reporting) 103
- 17.2 Reference laboratory monitoring 103
- 17.3 Sentinel laboratory monitoring 103
- 17.4 Special surveys 104
- 17.5 Surveillance based on routine susceptibility testing data 104
- 17.6 Prescribing data 104
- 17.7 Interplay of surveillance programme components 105
- 17.8 Additional needs for effective surveillance of resistance 105
- 17.9 Communication of local surveillance results 105

**18**

### **RESEARCH ON RESISTANCE AND ON NEW ANTIMICROBIAL AGENTS 107**

- 18.1 Public sector research on antimicrobial resistance 107

**19**

### **CHANGING PRACTICE 109**

- 19.1 Impact of guideline implementation on the process and outcome of care 110
- 19.2 Creating an environment for change 110

**20**

### **INDEPENDENT REVIEW OF THE LITERATURE 113**

- 20.1 Introduction 113
- 20.2 Aims 113
- 20.3 Methodology 113
- 20.4 Search results 114
- 20.5 Papers appraised 115

<b>21</b>	<b>REFERENCES</b> 130
<b>22</b>	<b>LIST OF RECOMMENDATIONS</b> 142 22.1 Implementation of Recommendations 145
<b>23</b>	<b>GLOSSARY OF TERMS</b> 146
<b>24</b>	<b>ACKNOWLEDGEMENTS</b> 151
<b>25</b>	<b>MEMBERSHIP OF SUB-GROUP</b> 152

<b>Figure 1</b>	Recommendations for the professions and the public: CATNAP 13
<b>Figure 2</b>	Complications after appropriate, changed and inappropriate antibacterial therapy in surgical patients with peritonitis 15
<b>Figure 3</b>	Mechanisms of antibacterial resistance 20
<b>Figure 4</b>	Plasmids and transposons: genetic mechanisms of resistance transfer 21
<b>Figure 5</b>	Anti-infective items prescribed per person for health districts and regions, 1996 30
<b>Figure 6</b>	Use of antimicrobial agents in a teaching hospital trust 30
<b>Figure 7</b>	The pyramids of antimicrobial use and selection for antimicrobial resistance 31
<b>Figure 8</b>	Proportion (%) of <i>Staphylococcus aureus</i> isolates from blood and CSF that were resistant to methicillin, 1989–97 34
<b>Figure 9</b>	Number of hospitals submitting enterococci resistant to glycopeptides to the PHLS Antibiotic Reference Unit: England and Wales, 1987–96 36
<b>Figure 10</b>	Resistance to penicillin in <i>Streptococcus pneumoniae</i> : several European countries 38
<b>Figure 11</b>	Resistance to antibacterial agents of <i>Salmonella typhimurium</i> DT 104 isolated from man: England and Wales, 1982–96 42
<b>Figure 12</b>	Proportion of clinical <i>Neisseria meningitidis</i> isolates highly sensitive to penicillin (MIC <0.1 mg/l) 46
<b>Figure 13</b>	Tetracycline-resistant <i>Escherichia coli</i> in the pig population 83
<b>Figure 14</b>	Gentamicin resistance after formulary substitution by amikacin 86
<b>Figure 15</b>	Advertising to discourage antibiotic use 101
<b>Figure 16</b>	Patient information leaflet 101
<b>Table 1</b>	The number of prescriptions (thousands) for antimicrobial agents dispensed in England: 1993–96 17
<b>Table 2</b>	The major classes of antibacterial agents and the sources of resistance 18
<b>Table 3</b>	Resistance to other antibacterial agents in <i>Streptococcus pneumoniae</i> sensitive and resistant to penicillin: data from 10 European centres 23
<b>Table 4</b>	Resistance to other antimicrobial agents in klebsiellae susceptible and resistant to cephalosporins: data from a European study 31
<b>Table 5</b>	Total use of systemic antimicrobial agents in the the community and hospitals in the UK 32
<b>Table 6</b>	Bacterial resistance in the UK 32
<b>Table 7</b>	Incidence of MRSA in different parts of the world 34
<b>Table 8</b>	Prevalence of resistance to antibacterial agents in <i>Streptococcus pneumoniae</i> : England and Wales 37
<b>Table 9</b>	Prevalence of resistance to penicillin G and erythromycin in <i>Streptococcus pneumoniae</i> isolates from blood and CSF: England and Wales, 1989–95 37
<b>Table 10</b>	Resistance (%) to antibacterial agents in gram-negative bacteria from blood and CSF: England and Wales, 1989–97 40
<b>Table 11</b>	Resistance (%) to antibacterial agents in gram-negative bacteria: USA, 1989–94 40
<b>Table 12</b>	Resistance (%) to antimicrobial agents in salmonellae: England and Wales, 1994 and 1996 41
<b>Table 13</b>	Resistance to antibacterial agents in <i>Campylobacter</i> spp isolated from man: England and Wales, 1997 43
<b>Table 14</b>	Resistance to penicillin in <i>Neisseria gonorrhoeae</i> isolates: County of Avon, 1988–96 45

<b>Table 15</b>	Susceptibility to ciprofloxacin of all <i>Neisseria gonorrhoeae</i> isolated in the County of Avon 1988–96	56
<b>Table 16</b>	Antifungal agents available in the UK	49
<b>Table 17</b>	Antiviral agents licensed or available for compassionate use in the UK (June 1998)	50
<b>Table 18</b>	Resistance (%) of <i>Pseudomonas aeruginosa</i> isolates by patient group: UK	56
<b>Table 19</b>	Antibacterial agents prescribed by dentists as percentages of all agents dispensed in the community in England, 1993–96	57
<b>Table 20</b>	Antibacterial agents prone to select resistance by mutation	62
<b>Table 21</b>	Information available in 23 sets of prescribing guidelines for acute otitis media, collected from PHLS laboratories	66
<b>Table 22</b>	GPs' certainty about the need for antibiotics when prescribing for lower RTI	73
<b>Table 23</b>	New antibacterial agents under development 1998	88
<b>Table 24</b>	Effects of rapidly available data on empirical therapy in bacteraemia	96

<b>Box 1</b>	Terms of Reference	7
<b>Box 2</b>	Four things you can do	9
<b>Box 3</b>	Multi-resistance	22
<b>Box 4</b>	The antimicrobial tug of war	25
<b>Box 5</b>	The painful ear	26
<b>Box 6</b>	The sore throat	27
<b>Box 7</b>	Sinusitis	27
<b>Box 8</b>	Cystitis (urinary tract infection)	28
<b>Box 9</b>	Endocarditis (infection of the heart valves)	58
<b>Box 10</b>	Guidelines for antimicrobial agents	66
<b>Box 11</b>	Justifications for prescribing	67
<b>Box 12</b>	Recommendations for prophylaxis in surgery	69
<b>Box 13</b>	Better prescribing	92
<b>Box 14</b>	Aspects meriting further research	108